Oral Agents for Treatment of Patients with Advanced Pancreatic Neuroendocrine Tumors: Could Pharmaeconomic, Cost-Effectiveness Data Play a Significant Role?
Downloads
References
Oberstein PE, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors. Highlights from the “2012 ASCO Annual Meeting”, Chicago, IL, USA; May 31-June 5, 2012. JOP. J Pancreas (Online) 2012; 13:372-75.
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063- 72
Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12: 1083-92
Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G. Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opin Ther Targets 2012; 16, Suppl 2:S91-102
Strimpakos AS, Syrigos KN, Saif MW. Pancreatic neuroendocrine tumors: role of novel agents. JOP. J Pancreas (Online) 2011; 12: 117-9
Rinke A, Móller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-63
Liakakos T, Roukos DH. Everolimus and sunitib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncol 2011; 7: 1025-9
Yao JC, Shah MH, Ito T, Lombard Bohas C, Wolin EM, Van Cutsen E et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364; 514-23
Ebos JM, Kerbel RS. Antiangiogenetic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 316-21
Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical nonredundant role in angiogenic swithching and pancreatic βcell carcinogenesis. Cancer Cell 2002; 1: 193-202
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard Bohas C et al. Sunitib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364; 501-13
Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011; 364: 564-5
Signorovitch J, Shallow E, Kantor E. Overall survival with everolimus, sunitib, and placebo for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison of randomized trials. J Clin Oncol 2012; 30 (Suppl 1): 237
Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP. Cost-effectivenes of everolimus vs sunitib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ 2012; 15 (suppl S1): 55-64
Casciano R, Chulikavit M, Di Lorenzo G, Liu Z, Baladi JF, Wang X, Robertson J, Garrison L. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health; 2011:14:846-51
Copyright (c) 2014 Maria Elisa Barna, Ilaria Uomo, Maurizio Pastorello
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.